Priv. Doz. Dr. Niklas Zojer
Zojer N, Ludwig H. Chronic lymphocytic leukaemia – emerging treatment options: a report from the ASH Meeting 2009. Memo 2010. Vol 3: 65-68
Ludwig H, Adam Z, Tothova E, Hajek R, Labar B, Egyed M, Spicka I, Gisslinger H, Drach J, Kuhn I, Hinke A, Zojer N. Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma. Haematologica. 2010 Apr 23.
Ludwig H, Zojer N. Renal recovery with lenalidomide in a patient with bortezomib-resistant multiple myeloma. Nat Rev Clin Oncol. 2010 May;7(5):289-94.
Ludwig H, Hajek R, Tothova E, Drach J, Adam Z, Labar B, Egyed M, Spicka I, Gisslinger H, Greil R, Kuhn I, Zojer N, Hinke A. Thalidomide-dexamethasone compared to melphalan-prednisolone in elderly patients with multiple myeloma. Blood. 2009; 113(15):3435-42.
Ludwig H, Zojer N. Recent therapeutic advances in hematological malignancies: dealing with treatment-related complications. Ann Oncol. 2008 Jul;19 Suppl 5:v71-8.
Zojer N, Mirzaei S, Ludwig H. Successful treatment of a patient with lymphocyte-predominant Hodgkin’s lymphoma with yttrium-90-ibritumomab tiuxetan. Eur J Haematol. 2008 Jun 25.
Heintel D, Zojer N, Schreder M, Strasser-Weippl K, Kainz B, Vesely M, Gisslinger H, Drach J, Gaiger A, Jäger U, Ludwig H. Expression of MUM1/IRF4 mRNA as a prognostic marker in patients with multiple myeloma. Leukemia 2008 Feb;22(2):441-5.
Ludwig H, Zojer N. Supportive care in multiple myeloma. Best Practice & Research Clinical Haematology Vol. 20, No. 4, pp. 817–835, 2007
Ludwig H, Strasser-Weippl K, Schreder M, Zojer N. Advances in the treatment of hematological malignancies: current treatment approaches in multiple myeloma. Ann Oncol. 2007 Jul;18 Suppl 9:ix64-70
Ludwig H, Zojer N, Drach J. The impact of novel agents in patients with poor prognosis myeloma defined by unfavorable cytogenetics, high age, and renal failure. Proceedings of the XI International Myeloma Workshop, Kos, June 2007.
Heintel D, Zojer N, Schreder M, Strasser-Weippl K, Kainz B, Vesely M, Gisslinger H, Drach J, Gaiger A, Jager U, Ludwig H. Expression of MUM1/IRF4 mRNA as a prognostic marker in patients with multiple myeloma. Leukemia. 2007 Aug 9, 1-4.
Zojer N, Ludwig H. Hematological emergencies. Ann Oncol. 2007 Feb;18 Suppl 1:i45-i48.
Sagaster V, Kaufmann H, Odelga V, Ackermann J, Gisslinger H, Rabitsch W, Zojer N, Ludwig H, Nosslinger T, Zielinski C, Drach J. Chromosomal abnormalities of young multiple myeloma patients. Eur J Haematol. 2007 Mar;78(3):227-34.
Ludwig H, Zojer N. Supportive care. Ann Oncol. 2007 Feb;18 Suppl 1:i37-i44.
Zojer N, Brenner K, Beke D, Kudlacek S, Hawa G, Woloszczuk W, Hofbauer LC, Pecherstorfer M. Bisphosphonate treatment does not affect serum levels of osteoprotegerin and RANKL in hypercalcemic cancer patients. Anticancer Res. 2005 Sep-Oct;25(5):3607-12.
Sahota SS, Babbage G, Zojer N, Ottensmeier CH, Stevenson FK. Determining mutational status of immunoglobulin v genes in chronic lymphocytic leukemia: a useful prognostic indicator. Methods Mol Med. 2005;115:129-44.
Massoner A, Augustin F, Duba HC, Zojer N, Fiegl M. FISH cytogenetics and prognosis in breast and non-small cell lung cancers. Cytometry B Clin Cytom. 2004 Nov;62(1):52-6.
Babbage G, Garand R, Robillard N, Zojer N, Stevenson FK, Sahota SS. Mantle cell lymphoma with t(11;14) and unmutated or mutated VH genes expresses AID and undergoes isotype switch events. Blood. 2004 Apr 1;103(7):2795-8.